Inhibrx INBX
$ 13.95
-0.64%
Annual report 2023
added 02-28-2024
Country |
USA |
IPO year |
2020 |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBAL |
CEO |
Mr. Mark Paul Lappe |
Employees in the company |
75 |
Shares |
47.1 M |
Market Cap[1] |
$ 657 M |
EBITDA (LTM) |
$ -160 M |
P/E (LTM) |
-4.32 |
P/S (LTM) |
1639.55 |
EPS (LTM) |
-4.2 |
Other stocks of industry "Biotechnology"
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.